Search

Displaying results 2981 - 2990 of 4301 in total
  1. Drug

    Oleoyl-estrone

    go.drugbank.com/drugs/DB04870
    Investigational

    Body protein loss is an unpleasant effect of fat loss by the restriction of calories, and studies show that this drug appears to avoid this effect.

  2. Drug

    Oxyquinoline

    go.drugbank.com/drugs/DB11145
    ApprovedInvestigationalVet approved

    Oxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and pesticide properties. It is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products.

  3. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation of inhibitory pathways preventing pain signals from reaching the brain.

  4. Drug

    Amifampridine

    go.drugbank.com/drugs/DB11640
    Approved

    Firdapse (amifampridine) was formally approved by the US FDA for the treatment of adults with LEMS as recently as November of 2018 [L4819]. … It was demonstrated in clinical studies involving healthy volunteers that the pharmacokinetics and systemic exposure to amifampridine is affected by the genetic differences in N-acetyl-transferase (NAT

  5. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

  6. Drug

    D-Proline

    go.drugbank.com/drugs/DB02853
    Experimental

    These amino acids may be of bacterial origin, but there is also evidence that they are endogenously produced through amino acid racemase activity [A19263].

  7. Drug

    Besifloxacin

    go.drugbank.com/drugs/DB06771
    Approved

    Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.

  8. Drug

    AZD-9684

    go.drugbank.com/drugs/DB05712
    Experimental

    It is being developed by AstraZeneca.

  9. Drug

    ALKS 29

    go.drugbank.com/drugs/DB05723
    Experimental

    It is being developed by Alkermes, Inc.

  10. Drug

    PLT012

    go.drugbank.com/drugs/DB23610
    Investigational

    PLT012 is a humanized anti-CD36 antibody developed by Pilatus Biosciences for treating liver cancer and intrahepatic bile duct cancer.